The gut microbiota are mainly composed of Bacteroidetes and Firmicutes and are crucial for
metabolism and immunity. Muribaculaceae are a family of bacteria within the order …

Tumor necrosis factor-α (TNF-α) antagonists, the first biologics approved for treating patients
with inflammatory bowel disease (IBD), are effective for the induction and maintenance of …

Background We aimed to investigate the gut microbiota of patients with established
rheumatoid arthritis (RA) who have been managed with disease-modifying anti-rheumatic …

Patients with ulcerative colitis (UC) have low response rates to anti-integrin medications,
necessitating the identification of noninvasive biomarkers for predicting remission to anti …

The incidence of inflammatory bowel disease (IBD) is globally increasing. This disorder
seriously affects the quality of life in patients. Interestingly, studies have detected that the …

Nonresponse to biologic agents in patients with inflammatory bowel disease (IBD) poses a
significant public health burden, and the prediction of response to biologics offers valuable …

The consumption of similar diets has led to the convergence of gut microbial compositions
and functions across phylogenetically distinct animals. However, given the functional …

Inflammatory bowel disease (IBD) is a complex heterogeneous disorder defined by recurring
chronic inflammation of the gastrointestinal tract, attributed to a combination of factors …

Background and Aims: Anti-tumor necrosis factor mAb (ie, adalimumab, ADA) is currently
used in the treatment of patients with Crohn's disease (CD). However, its regulation on fecal …

Difenoconazole (DIF) is a widely separated triazole fungicide in many countries. The
excessive usage of DIF increases the high volume of residues in agriculture production and …